Floatz logo

Pelareorep

Anal Cancer Metastatic

Oncolytics Biotechgene_therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Anal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Federation Francophone de Cancerologie Digestive
Phase 3BB
Carboplatin
Dustin Deming
Phase 3BB
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Federation Francophone de Cancerologie Digestive
Phase 3BB

View all 50 →

Same molecule, other indications

Pelareorep is also rated in:

breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →